secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2026-06-17T12:05:40+00:00
Accession:  0001493152-26-028994
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra CEO details strategic pivot to cosmetic ingredients and recombinant proteins; pauses Netherton trial
--------------------------------------------------------------------------------

- Raised $10.5M in March with up to $21M additional from warrant exercises to fund new initiatives.
- Launches ATR-COSF, a recombinant filaggrin cosmetic ingredient; expects clinical study completion in late 2026.
- In-licenses FHCC minicircle plasmids showing 100,000x improvement; targets TEV protease and T7 RNA Polymerase market (~$1B).
- ATR-04 (EGFR inhibitor rash) continues enrollment with MD Anderson as new clinical site.
- Pauses ATR-12 Netherton trial enrollment to redirect capital to ATR-COSF near-term milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315226028994/0001493152-26-028994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315226028994/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-028994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer